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Summary  Neck  pain  affects  a  third  of  patients  following  head-and-neck  cancer  treatment,
whether  by  radiation  therapy  or  surgery.  It  is  a  disabling  condition  and  the  associated  mus-
cle contractures  impair  cervical  motion.  Type-A  botulinum  toxin  is  an  analgesic  and  muscle
relaxant,  able  to  improve  patients’  quality  of  life.  We  here  report  our  experience  with  botulinum
toxin in  post-radiosurgical  neck  contracture.
Patients  and  methods:  A  single-center  pilot  study  was  run  from  January  2007  to  July  2008,
respecting  the  Declaration  of  Helsinki.  All  patients  in  complete  remission  from  head-and-neck
cancer with  post-radiosurgical  neck  contracture  impairing  neck  motion  were  included.  Pain  and
functional  impairment  were  assessed  on  a  neck-function  disability  scale  before  and  1  month
after botulinum  toxin  injection.  Efﬁcacy  duration  was  measured.  Complications  at  the  injection
site or  related  to  drug  diffusion  were  investigated.
Results:  Nine  consecutive  patients  (six  male,  three  female;  mean  age,  61  years  [range,
52—73 years])  were  included.  In  six  patients,  the  sternocleidomastoid  muscle  was  injected  and
the muscular  pedicle  of  a  pectoralis  major  ﬂap  in  three.  Mean  cervical  disability  score  fell  sig-
niﬁcantly  from  33  to  23  (P  =  0.01).  There  were  no  complications.  Efﬁcacy  was  seen  at  a  mean
6 days,  and  analgesia  and  muscle  relaxation  lasted  for  a  mean  19  days.
Conclusion:  In  post-radiosurgical  neck  contracture,  botulinum  toxin  injection  is  a  simple  and
easy procedure  able  to  improve  neck  motion  and  reduce  neck  pain  in  head-and-neck  cancer
patients.  A  phase-II  prospective  study  to  determine  injection  sites  and  dosage  should  help  bear
out these  preliminary  ﬁndings.
.  All  © 2011  Elsevier  Masson  SAS∗ Corresponding author. Tel.: +33 1 46 25 22 31.
E-mail address: christine.bach@hopital-foch.org (C.-A. Bach).
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ntroductioneck  pain  affects  a  third  of  patients  following  head-and-
eck  cancer  treatment  [1],  whether  by  radiation  therapy
RT)  or  surgery.
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Figure  1  A.  Intramuscular  sternocleidomastoid  injection  at  a
peak contracture  point.  B.  Diagram  of  potential  sternocleido-
mastoid  injection  sites.
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Radiation-induced  toxicity  causes  progressive  tissue
sclerosis,  characteristic  of  post-RT  ﬁbrosis.  All  types
of  tissue  —skin,  muscle  and  nerve  —  may  be  involved,
especially  in  the  neck  [2,3]. Muscles  undergo  atrophy
and  ﬁbrosis,  inducing  permanent  involuntary  muscle-ﬁber
contracture,  accompanied  by  myalgia,  a  deep  dull  pain
which  may  be  exacerbated  by  spasms  and  muscle  cramp
[4].  Reduced  Schwann  cell  proliferation,  leading  to  long-
term  demyelinization  and  ﬁbrosis,  is  observed  in  peripheral
nerve  cells.  This  post-RT  peripheral  nervous  system  damage
and  surgical  dissection  of  the  neck  both  induce  neuropathic
pain.
Following  surgery  and  radiation  therapy,  the  sternoclei-
domastoid  (SCM)  muscle  undergoes  painful  contracture.  The
same  symptoms  occur  in  covering  ﬂaps  (e.g.,  pectoralis
major  muscle).  The  pain  is  disabling  and  the  contracture
impairs  neck  motion.  Post-radiosurgical  musculoskeletal
and  neuromuscular  lesions  are  a  major  cause  of  cancer
treatment-related  disability  [5].
Type-A  botulinum  toxin  is  an  analgesic  [6,7]  and  mus-
cle  relaxant,  should  be  able  to  provide  beneﬁt  in  patients
showing  painful  post-radiosurgical  cervical  contracture.  It
has  been  applied  in  chronic  neuropathic  pain  secondary  to
neck  dissection  [8,9]  and  in  post-RT  trismus  [10]. There  is
only  one  report  of  its  use  in  post-RT  SCM  spasm  [4].
We  report  our  experience  of  type-A  botulinum  toxin  in
post-radiosurgical  neck  contracture  in  head-and-neck  can-
cer  remission.
Patients and methods
A  single-center  pilot  study  was  run  from  January  2007  to
July  2008.  All  patients  in  complete  remission  of  head-and-
neck  cancer  and  showing  painful  neck  contracture  with
impaired  neck  motion  were  included.  Exclusion  criteria
were:  contra-indications  for  botulinum  toxin,  such  as  neuro-
logical  or  muscular  pathology  (amyotrophy,  cervical  axis  or
upper  limb  muscle  weakness,  or  myasthenia);  disabling  and
painful  cervical  spine  bone  pathology;  or  implanted  chamber
with  internal  jugular  vein  catheter  ipsilateral  to  the  contrac-
ture.  Patients  were  informed  by  the  surgeon  in  consultation
prior  to  injection  and  gave  written  consent  prior  to  treat-
ment  in  line  with  the  1983  Declaration  of  Helsinki.
Type-A  botulinum  toxin  was  Dysport® (Ipsen  Pharma,
Boulogne-Billancourt,  France),  reconstituted  with  2  ml
physiological  saline  for  a  concentration  of  25  Speywood
units/0.1  ml.
Contracture  was  deﬁned  as  permanent  involuntary
contraction  of  all  muscle  ﬁbers  of  the  region  of  interest.
Contracted  muscles  were  shortened  and  under  constant  ten-
sion,  clearly  visible  under  the  skin.  Palpation  found  a  ﬁrm
cord  with  intense  pain  points.  Injection  was  made  at  points
of  peak  contracture  (Fig.  1).
The  minimum  injection  dose  of  0.1  ml  (i.e.,  25  SU)  was
taken  from  the  only  report  published  on  the  question  [4].
Individual  doses  were  adapted  to  the  intensity  of  contrac-
ture  of  the  SCM  or  of  the  muscular  pedicle  of  a  covering
ﬂap,  as  assessed  by  palpation  and  patient’s  self-assessment
of  disability  at  interview,  and  ranged  from  0.1  to  0.2  ml
(25—50  SU)  per  injection  site.  Doses  delivered  to  a  given  SCM
muscle  ranged  from  100  to  400  SU  (three  to  eight  sites),  and
s
c
c
so  a  given  pectoralis  major  ﬂap  from  125  to  200  SU  (four  to
ve  sites).
Pain  and  functional  disability  were  assessed  by  two
ethods:  on  a  functional  disability  scale  for  neck  pain  before
nd  1  month  after  injection,  and  by  asking  the  patient  to
escribe  overall  improvement  in  neck  motion  as  none,  mod-
rate  or  very  good  1  month  after  injection.  Efﬁcacy  duration
as  assessed  by  interview  during  scheduled  follow-up.
The  functional  disability  scale  for  neck  pain  [11]  is  a
alidated  [12]  French  translation  adapted  from  the  Neck
isability  Index  [13], an  English-language  neck  pathology
ain  and  function  scale,  chosen  for  its  speciﬁcity  in  pain  and
unction  in  cervicalgia.  It  is  a  10-question  self-administered
uestionnaire,  with  six  possible  responses  per  question,
coring  0  (no  disability)  to  5  (total  disability).  The  questions
over  pain,  personal  care,  load  lifting,  reading,  headache,
oncentration,  work  (professional  or  personal),  driving,
leep  and  leisure.
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Table  1  Main  patient  characteristics.
Patient
no./Age
(years)
Tumor  location  TNM
classiﬁcation
Tumor  histology  Chemotherapy  Tumor  surgery  Cervical  node  radiation  therapy  (doses  in  Grays)
Anterior  cervical
chain
Supraclavicular
chain
Spinal
chain
1/65  Oropharynx  T4N1M0  squamous  cell
carcinoma
No  Flap  oropharyn-
gectomy,
ipsilateral  node
curage
50  45  0
2/54 Oral  cavity  T3N1M0  squamous  cell
carcinoma
Yes  Flap  oropharyn-
gectomy,
ipsilateral  node
curage
45  45  45
3/73 Oropharynx  T2N1M0  squamous  cell
carcinoma
No  Flap  oropharyn-
gectomy,
ipsilateral  node
curage
50  45  0
4/68 Endolarynx  then
soft  palate
T1N0M0
T1N0M0
squamous  cell
carcinoma
No
No
No  surgery,  Soft
palate
electroresec-
tion  +  ipsilateral
node  curage
62  Gy  to  laryngeal  nodes
5/64 Piriform  sinus  T3N0M0  squamous  cell
carcinoma
Yes  Ipsilateral  node
curage
44  54  60
6/58 Metastatic
adenopathy
N1M0  olfactory
neuroblastoma
No  Ipsilateral  node
curage
58  45  18
7/54 Metastatic
adenopathy
without
primitive
N2aM0  adenocarcinoma  Yes  Ipsilateral  node
curage
45  36  23
8/52 Piriform  sinus,
ﬂoor  of  the
mouth
T4N0M0
T2N0M0
squamous  cell
carcinoma
No  Total
pharyngolaryngec-
tomy  +  anterior
pelvectomy,
bilateral  node
curage
23  45  18
9/60 Oropharynx  T2N0M0  squamous  cell
carcinoma
No  Oropharyngectomy,
ipsilateral  node
curage
39  45  9
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Table  2  Main  patient  characteristics.  Injection  sites  and  doses.
Patient
no.
Age
(years)/Gender
End  RT
(months)
Injection
site
Bilateral
injection
Number  of  injection
points  ×  dose  (mL)
Total  units
injected  (U)
1  65/M  5  PMF  No  5  ×  0.1  125
2 54/M  24  PMF  No  5  ×  0.1  125
3 73/F  18  PMF  No  4  ×  0.2  200
4 68/M  36  SCM  No  4  ×  0.1  100
5 64/F  84  SCM  No  3  ×  0.2  150
6 58/M  15  SCM  No  5  ×  0.1  125
7 54/F 7  SCM  No  6  ×  0.2  300
8 52/M 15  SCM  Yes  5  ×  0.2  +  5  ×  0.2  500
9 60/M  48  SCM  Yes  8  ×  0.2  +  8  ×  0.2  800
mastoid muscle.
Table  3  Cervical  disability  score  before  and  1  month  after
injection,  and  overall  neck  motion  improvement.
Patient  no.  FDSNP  score
before
FDSNP  score
after
Neck  motion
improvement
1  50  34  Moderate
2 30 28 None
3 35  29  Moderate
4 36  25  Moderate
5 18  16  Moderate
6 44  25  Moderate
7 32 29  Moderate
8 30  25  Moderate
i
o
o
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f
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B
a
a
b
qM: male; F: female; PMF: pectoralis major ﬂap; SCM: sternocleido
Injection-related  (erythema,  pruritus,  skin  lesion)  and
diffusion-related  (neck  muscle  weakness,  dry  mouth,  dys-
phagia,  dyspnea)  local  complications  were  investigated.
Statistics
Statistical  analysis  used  S-PLUS  4.5  software.  Differences  in
overall  and  item  scores  before  and  after  injection  were
assessed  on  Wilcoxon  rank  test.  Mean  values  were  calcu-
lated  for  each  variable.  The  signiﬁcance  threshold  was  set
at  P  <  0.05.  All  tests  were  2-tailed.
Results
Nine  consecutive  patients  were  included:  six  male,  three
female;  mean  age,  61  years  (range,  52—73  years).  All  had
head-and-neck  carcinoma  in  remission.  All  had  undergone
uni-  (n  =  8)  or  bi-lateral  (n  =  1)  functional  cervical  dissec-
tion  without  spinal  nerve  involvement;  the  bilateral  curage
was  performed  during  total  pharyngolaryngectomy.  Patients
with  a  pectoralis  major  covering  ﬂap  (n  =  3)  had  undergone
transmandibular  conservative  approach  oropharyngectomy
conserving  the  mandibula  for  oropharyngeal  or  mouth  cav-
ity  lesion.  All  patients  had  undergone  postoperative  external
radiation  therapy.  Table  1  presents  the  patient  characteris-
tics.
Botulinum  toxin  treatment  was  administered  at  a  mean
28  months  (range,  5—84  months)  post-RT  (Table  2).
In  six  patients,  injection  was  to  the  SCM  (bilaterally  in
two),  and  in  three  to  the  muscular  pedicle  of  a  pectoralis
major  ﬂap  (Table  2).  In  one  patient,  injection  was  performed
under  local  anesthesia  using  Emla®.
Post-injection  overall  cervical  disability  scores  showed
improvement  in  eight  patients  (89%)  (Table  3):  mean  score
fell  signiﬁcantly,  from  33  (range,  18—50)  to  23  (16—34)
(P  =  0.01).  Scores  showed  signiﬁcant  improvement  on  four
items:  pain  (P  =  0.01),  load  lifting  (P  =  0.05),  work  (P  =  0.03)
and  leisure  (P  =  0.01).
Two  patients  reported  no  improvement  in  neck  motion
with  injection,  although  one  in  fact  reported  a  2-point
m
T
o9 25  25  None
FDSNP: functional disability scale in neck pain.
mprovement  in  overall  disability  (the  other,  no  change).  The
ther  patients  (77%)  reported  moderate  improvement.
There  were  no  complications.  Efﬁcacy  was  observable  as
f  a  mean  of  6  days  (range,  D0  to  1  month),  for  a  mean  of
9  days  (range,  D0  to  2  months).
No  recurrence  of  the  initial  pathology  was  observed  over
ollow-up.
iscussion
otulinum  toxin  injected  to  the  neck  muscles  reduced  pain
nd  improved  neck  motion.  Certain  everyday  activities,  such
s  lifting  loads,  being  able  to  work  without  being  hindered
y  pain  and  leisure  activities,  were  improved,  enhancing
uality  of  life.
The  cervical  disability  score  showed  signiﬁcant  improve-
ent  (P  =  0.01)  in  89%  of  cases  (eight  patients  out  of  nine).
hese  results  are  equivalent  to  those  of  a  study  in  which  87%
f  patients  receiving  type-A  botulinum  toxin  injection  for
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ost-RT  head-and-neck  ﬁbrosis  syndrome  reported  beneﬁt
5];  injection  was  indicated  for  cervical  dystonia,  migraine,
rigeminal  and  cervical  plexus  neuralgia,  trismus  and  chest
ain.
Botulinum  toxin  demonstrated  a  signiﬁcant  analgesic
ffect  (P  =  0.01)  and  moderately  improved  neck  motion.  In
hronic  neuropathic  pain,  analgesia  can  be  obtained  with
imple  subcutaneous  injection  in  the  painful  region  [6].  In
he  present  study,  injection  was  intramuscular  at  the  peak
ontracture  points  of  elevated  pain.  Although  the  peripheral
ervous  system  is  damaged  within  irradiated  muscle  by  the
schemia  induced  by  progressive  ﬁbrosis  stenosing  the  vasa
asorum  and  by  external  skin  and  soft  tissue  pressure  [5],
otulinum  toxin  is  nevertheless  able  to  act  on  peripheral
ociceptive  ﬁbers  [7].
Peripheral  nervous  system  lesions  and  muscle  ﬁbrosis
educe  the  number  of  neuromuscular  junctions  available
o  receive  the  toxin  and  hence  the  muscle-relaxant  effect,
ccounting  for  the  only  moderate  improvement  in  neck
otion.
The  same  reasons  probably  underlie  the  short  efﬁcacy
ime  of  the  analgesic  and  relaxant  effects  (mean  =  19  days).
oxin  diffusion  patterns  within  the  irradiated  muscle  remain
nknown.  Two  patients  reported  an  immediate  effect,  which
as  surprising  as  botulinum  toxin  usually  takes  24—36  hours
o  act.
A  limitation  of  the  present  study  lay  in  sample  size  and
eterogeneity.  Either  one  or  two  SCM  muscles  or  a ﬂap
uscular  pedicle  were  injected.  On  the  other  hand,  symp-
omatology  was  systematic:  painful  post-radiation  muscle
brosis  and  cervical  disability.  All  patients  were  satisﬁed
ith  their  treatment,  in  the  absence  of  alternative.
Only  two  other  articles  on  this  topic  could  be  found  in  the
iterature  [4,5], and  no  useful  comparison  could  be  made.
The  present  assessment  criteria  are  open  to  criticism.
ome  of  the  cervical  disability  scale  items,  concerning
eading,  work  (professional  or  personal),  driving  and  leisure,
ere  not  well-suited  to  the  target  population,  characterized
y  alcohol  and  nicotine  abuse.  The  questionnaire  failed
o  provide  precise  assessment  of  subjective  impairment
r  objective  assessment  of  improvement  in  neck  motion:
ven  when  the  reduction  in  disability  score  was  consider-
ble,  patients  reported  only  moderately  improved  motion.
t  would  be  interesting  to  use  a  different  scale,  the  Neck  Pain
nd  Disability  Scale  [14]  and  a  quality  of  life  questionnaire
uch  as  the  QLQ-H&N35  [15].
The  present  ﬁndings  encourage  further  investigation.  A
rospective  phase-II  study  has  been  launched  to  determine
njection  sites  and  botulinum  toxin  dosage  in  unilateral  post-
adiation  cervical  contracture  in  patients  in  remission  of
ead-and-neck  cancer.
onclusion
rogress  in  anticancer  treatments  is  increasing  survival,  but
ith  associated  sequelae  that  must  be  taken  into  account
n  order  to  improve  quality  of  life  in  complete  remission.
hese  patients  are  ever  more  demanding,  especially  those
ho  are  young  and  free  of  risk  factors,  who  wish  quickly  to
ecover  a  quality  of  life  allowing  occupational  and  personal
ctivity.
[C.-A.  Bach  et  al.
Type-A  botulinum  toxin  injection  in  post-radiosurgical
eck  contracture  is  a  simple  and  easy  procedure  that
mproves  motion  and  reduces  pain,  thus  contributing  to
ecovery  of  cervical  function.
The  present  preliminary  study  enabled  better  control  of
he  toxin  in  irradiated  muscle.  It  remains  to  determine  injec-
ion  sites  and  dosage  so  as  to  optimize  results  and  extend
fﬁcacy  duration.
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
eferences
[1] Navez ML. Otolaryngological cancer pain at the after-
effects stage. Ann Otolaryngol Chir Cervicofac 2007;124(Suppl
1):S39—44.
[2] Hauer-Jensen M, Fink LM, Wang J. Radiation injury and the
protein C pathway. Crit Care Med 2004;32:S325—30.
[3] Gillette EL, Mahler PA, Powers BE, et al. Late radiation injury
to muscle and peripheral nerves. Int J Radiat Oncol Biol Phys
1995;31:1309—18.
[4] Van Daele DJ, Finnegan EM, Rodnitzky RL, et al. Head and
neck muscle spasm after radiotherapy: management with
botulinum toxin A injection. Arch Otolaryngol Head Neck Surg
2002;128:956—9.
[5] Stubbleﬁeld MD, Levine A, Custodio CM, et al. The role
of botulinum toxin type A in the radiation ﬁbrosis syn-
drome: a preliminary report. Arch Phys Med Rehabil 2008;89:
417—21.
[6] Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A
induces direct analgesic effects in chronic neuropathic pain.
Ann Neurol 2008;64(3):274—83 [Erratum in: Ann Neurol. 2009
Mar;65(3):359].
[7] Ranoux D, Attal N, Morain F, et al. Botulinum toxin type A
induces direct analgesic effects in chronic neuropathic pain.
Ann Neurol 2008;64:274—83.
[8] Wittekindt C, Liu WC, Preuss SF, et al. Botulinum toxin A for
neuropathic pain after neck dissection: a dose-ﬁnding study.
Laryngoscope 2006;116:1168—71.
[9] Vasan CW, Liu WC, Klussmann JP, et al. Botulinum toxin type A
for the treatment of chronic neck pain after neck dissection.
Head Neck 2004;26:39—45.
10] Hartl DM, Cohen M, Julieron M, et al. Botulinum toxin for
radiation-induced facial pain and trismus. Otolaryngol Head
Neck Surg 2008;138:459—63.
11] Wlodyka-Demaille S, Poiraudeau S, Fermanian J, et al. French
translation and validation of a Functional Disability Scale for
neck pain. Ann Readapt Med Phys 2001;44:132—42.
12] Wlodyka-Demaille S, Poiraudeau S, Catanzariti JF, et al.
French translation and validation of three functional disabil-
ity scales for neck pain. Arch Phys Med Rehabil 2002;83:
376—82.
13] Vernon H, Mior S. The Neck Disability Index: a study of
reliability and validity. J Manipulative Physiol Ther 1991;14:
409—15.
14] Wlodyka-Demaille S, Poiraudeau S, Catanzariti JF, et al. The
ability to change of three questionnaires for neck pain. Joint
Bone Spine 2004;71:317—26.15] Bjordal K, Hammerlid E, Ahlner-Elmqvist, et al. Quality of life
in head and neck cancer patients: validation of the European
Organization for Research and Treatment of Cancer Quality of
Life Questionnaire-H&N35. J Clin Oncol 1999;17:1008—19.
